GeneBioTech Ltd Balance Sheet Health
Financial Health criteria checks 6/6
GeneBioTech has a total shareholder equity of ₩49.1B and total debt of ₩13.6B, which brings its debt-to-equity ratio to 27.6%. Its total assets and total liabilities are ₩69.4B and ₩20.3B respectively. GeneBioTech's EBIT is ₩4.0B making its interest coverage ratio -28.4. It has cash and short-term investments of ₩23.3B.
Key information
27.6%
Debt to equity ratio
₩13.55b
Debt
| Interest coverage ratio | -28.4x |
| Cash | ₩23.30b |
| Equity | ₩49.11b |
| Total liabilities | ₩20.26b |
| Total assets | ₩69.37b |
Recent financial health updates
Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17
Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Recent updates
We Like The Quality Of GeneBioTech Ltd's (KOSDAQ:086060) Earnings
Mar 22
Read This Before Buying GeneBioTech Co. ,Ltd (KOSDAQ:086060) For Its Dividend
Apr 15Should GeneBioTech Ltd (KOSDAQ:086060) Be Disappointed With Their 90% Profit?
Mar 18Here's Why Genebiotech (KOSDAQ:086060) Has A Meaningful Debt Burden
Feb 17How Does Genebiotech Co., Ltd. (KOSDAQ:086060) Fare As A Dividend Stock?
Jan 10Is Genebiotech (KOSDAQ:086060) A Risky Investment?
Nov 19Financial Position Analysis
Short Term Liabilities: A086060's short term assets (₩52.7B) exceed its short term liabilities (₩17.1B).
Long Term Liabilities: A086060's short term assets (₩52.7B) exceed its long term liabilities (₩3.2B).
Debt to Equity History and Analysis
Debt Level: A086060 has more cash than its total debt.
Reducing Debt: A086060's debt to equity ratio has reduced from 40.4% to 27.6% over the past 5 years.
Debt Coverage: A086060's debt is well covered by operating cash flow (41.2%).
Interest Coverage: A086060 earns more interest than it pays, so coverage of interest payments is not a concern.